Seattle Genetics: Clinical Trials: Hodgkin Lymphoma

Information for Patients and Physicians

Hodgkin lymphoma is one of two major categories of lymphoma. It is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen. According to the American Cancer Society, approximately 8,500 people will be diagnosed with Hodgkin lymphoma in the United States during 2010.

For more detailed information about the clinical trials summarized below, click on the link to the trial listing at www.clinicaltrials.gov.

HODGKIN LYMPHOMA CLINICAL TRIALS

Brentuximab vedotin (SGN-35) pivotal trial

Single-arm trial being conducted under a Special Protocol Assessment (SPA) to assess efficacy and safety of single-agent brentuximab vedotin in 100 patients with relapsed or refractory Hodgkin lymphoma
Enrollment to this trial is complete.

See Study Details ›

Brentuximab vedotin phase III AETHERA trial

Randomized, double-blind trial evaluating brentuximab vedotin versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant

See Study Details ›

Brentuximab vedotin phase II trial for retreatment of patients who previously participated in a brentuximab vedotin study

Evaluating the potential for retreatment with brentuximab vedotin in patients who have relapsed after discontinuing previous brentuximab vedotin therapy

See Study Details ›

Brentuximab vedotin phase I trial in combination with chemotherapy for front-line treatment of Hodgkin lymphoma

Evaluating the safety of combining brentuximab vedotin with Adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD) in newly diagnosed Hodgkin lymphoma patients

See Study Details ›

HODGKIN LYMPHOMA PATIENT RESOURCES

If you have questions about the Hodgkin lymphoma clinical trials, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Additional information about cancer, lymphoma and participating in clinical trials can be found on the following web sites.